Addiction is a widespread crisis in the United States that doesn’t seem to have an end in sight. Both youth and adults suffer the devastating consequences of drug and alcohol addiction, and lives are lost and families are torn apart every day due to its destructive effects. In 2015 alone, more than 50,000 deaths resulted from drug overdoses in the U.S. (http://dtn.fm/2IdEz), but one company is offering new hope to millions of addicted individuals and their loved ones and making major strides to help turn the tide in America’s addiction epidemic.
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company engaged in developing and providing cutting-edge solutions to treat alcohol and opioid addictions. The company has pioneered a fresh approach to addiction treatment, offering a non-addictive, medication-assisted treatment (MAT) program that consists of two main parts: an outpatient implant procedure performed by a licensed physician and a specially tailored one-on-one counseling program.
The first component of the BioCorRx Recovery Program involves the insertion of an implant that delivers naltrexone to addiction patients. Naltrexone is a non-addictive opioid antagonist that is able to significantly reduce an individual’s physical cravings for opioids and alcohol. The presence of the implant and its ongoing delivery of naltrexone make part two of the BioCorRx Recovery Program possible: one-on-one counseling that is specifically designed to treat the substance abuse addictions of patients receiving long-term naltrexone treatment. Because their addiction cravings have been quelled by the naltrexone, patients are able to make greater progress in psychosocial treatment and can more effectively address the underlying issues driving their addictive behaviors. The result is a much greater chance for patients to achieve long-term sobriety.
BioCorRx CEO Brady Granier recently discussed this revolutionary new treatment program on FOX News (http://dtn.fm/aWB4K) and FOX Business (http://dtn.fm/jZg1Z), detailing the BioCorRx program and the success it is having among patients. Granier also discussed an injectable naltrexone option the company currently has in preclinical development. Through BioCorRx Pharmaceuticals, an R&D subsidiary of BioCorRx, the company is developing, in partnership with TheraKine LTD, a new injection delivery technology for naltrexone called BICX101. This injectable naltrexone offers an additional naltrexone delivery option for addicted individuals in treatment.
BioCorRx also recently announced it has entered into an agreement with DynamiCare Health, Inc. to develop a co-branded mobile application, called DynamiCare Rewards™, with BioCorRx CBT that supports patients who are in treatment for addiction. This app will provide patients with a self-guided, interactive version of the BioCorRx Recovery Program and will enable counselors to remotely monitor their patients’ progress as patients complete the 35 modules of the program.
The tremendous success of BioCorRx’s twofold addiction treatment program—addressing both the physical and psychological aspects of opioid and alcohol addiction—is offering fresh hope for addicted individuals and their loved ones throughout the country.
For more information, visit the company’s website at www.BioCorRx.com